FDA limits use of J&J COVID vaccine over blood clot risk | Just The News

The U.S. Food and Drug Administration on Thursday announced it has limited the use of Johnson & Johnson's Janssen Pharmaceuticals COVID-19 vaccine over concerns associated with blood clots.

The FDA said the Janssen vaccine is now only authorized for use in adults “for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate” and for adults who “elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.”

The agency determined that the risk of thrombosis with thrombocytopenia syndrome (TTS), which can cause rare but potentially life-threatening blood clots one to two weeks after receiving the J&J vaccine, warrants limiting the shot's authorized use.

FDA official Dr. Peter Marks said, “We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community. Our action reflects our updated analysis of the risk of TTS following administration of this vaccine and limits the use of the vaccine to certain individuals.”